Back to company

Novo Nordisk North America Operations A/S: Financial statements 2025

CVR: 33761201

Novo Nordisk North America Operations A/S (CVR 33761201) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -59,000 and a net result of DKK -74,142,000 compared with DKK -89,167,000 the year before. Equity amounted to DKK 60,045,000. The solvency ratio was 5.2%.

Gross Profit
-59,000 kr.
Profit/Loss
-74,142,000 kr.
Equity
60,045,000 kr.
Total Assets
1,158,586,000 kr.
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--59 t.-74.1 mio.60 mio.0
2024--119 t.-89.2 mio.438.3 mio.-
20230-365 t.1.1 mia.1.1 mia.-
202231.3 mio.448 mio.334.3 mio.639.2 mio.-
2021188.9 mio.--467 mio.7.8 mia.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Novo Nordisk North America Operations A/S

Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.

Try the lead list generator

Events in 2025

Naja Eilers Barrisøe joins the board of Novo Nordisk North America Operations A/SDec 8, 2025

As of December 8, 2025, Naja Eilers Barrisøe has joined the board of directors of Novo Nordisk North America Operations A/S.

Karsten Munk Knudsen leaves the board of Novo Nordisk North America Operations A/SDec 8, 2025

As of December 8, 2025, Karsten Munk Knudsen has left the board of directors of Novo Nordisk North America Operations A/S.

Novo Nordisk North America Operations A/S: The 2024 annual report is outJun 3, 2025

Novo Nordisk North America Operations A/S has published its annual report for 2024. Gross profit came to DKK -119,000, and the net result was DKK -89,167,000.

About Novo Nordisk North America Operations A/S

Novo Nordisk North America Operations A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2011. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named Novo Nordisk Invest 3 A/S and NOVO NORDISK REGION NORTH AMERICA II A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. In 2025, the company reported a gross profit of DKK -59,000 and a net result of DKK -74,142,000 compared with DKK -89,167,000 the year before. Equity amounted to DKK 60,045,000.